NeOnc to Present NEO100, NEO212 Data at SNO
NeOnc Technologies will share two poster presentations on its central nervous system cancer therapies at the Society for Neuro-Oncology annual meeting in Philadelphia.
Updated on Nov. 2, 2026 in Cancer
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, will present data from its NEO100 and NEO212 programs in two posters at the 31st Annual Meeting of the Society for Neuro-Oncology. The posters are scheduled for Friday, November 13, 2026, from 7:30 to 9:30 p.m. EST at the Pennsylvania Convention Center.
Why it matters
The presentations give clinicians and researchers a look at investigational intranasal and oral approaches for brain tumors, including recurrent glioblastoma and brain metastases. NEO100 and NEO212 remain investigational, and their safety and efficacy have not been established.
The NEO100 poster reports results from a Phase 1/2a study in recurrent WHO Grade III/IV IDH1-mutant astrocytoma, and the NEO212 poster reports Phase 1 safety and pharmacokinetic data in TMZ-resistant recurrent GBM and brain metastases. Neither presentation's full efficacy conclusions are available in the source, and the clinical potential of both candidates remains uncertain.
The players
NeOnc Technologies Holdings, Inc.
NeOnc Technologies is a clinical-stage biopharmaceutical company headquartered in Calabasas, California, developing therapies for central nervous system cancers.
Society for Neuro-Oncology
The Society for Neuro-Oncology is a professional organization of researchers and clinicians focused on brain and spinal cord tumors, which hosts an annual scientific meeting.
The details
NEO100 is a highly purified form of perillyl alcohol administered intranasally, while NEO212 is an investigational oral conjugate of temozolomide and NEO100. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California covering both candidates and other drug delivery approaches.
Timeline
November 12 to 15, 2026: 31st Annual Meeting and Education Day of the Society for Neuro-Oncology
Friday, November 13, 2026, 7:30 to 9:30 p.m. EST: NeOnc poster presentations
Clinical Landscape
Intranasal delivery of drugs to the brain is being explored by researchers at the Society for Neuro-Oncology's annual meeting as a way to bypass the blood-brain barrier. NEO100 and NEO212 are presented as early-stage efforts within that broader investigational field, and their outcomes will depend on later-phase trials.
Patients with recurrent glioblastoma or brain metastases should note that NEO100 and NEO212 are investigational and not available as treatments. Any future access would depend on completed clinical trials and regulatory review, and the outcomes of those studies remain unknown.
The takeaway
Investigational brain cancer therapies remain early in development, and the presentations are best read as preliminary findings rather than evidence of clinical benefit. Patients and caregivers should discuss any trial options with their oncology team.
What happens next
NeOnc's poster presentations are scheduled for Friday, November 13, 2026, from 7:30 to 9:30 p.m. EST at the Society for Neuro-Oncology's 31st Annual Meeting in Philadelphia.
Further reading
Explore more cancer research and treatment news to see how investigational brain tumor therapies are advancing.
More information
Learn more on the NeOnc Technologies company website.
